Method of reducing collateral flow in a portion of a lung

• US 20050288684A1
• Filed: 06/14/2005
• Published: 12/29/2005
• Est. Priority Date: 06/16/2004
• Status: Abandoned Application

• Current Assignee: PneumRx, Inc. (Boston Scientific Corporation)
• Original Assignee: PneumRx, Inc. (Boston Scientific Corporation)
• Inventors: Wartchow, Charles A., Gong, Glen, Aronson, Nathan A.
• Application Number:
  US11/153,233
• Publication Number:
  US 20050288684A1
• Time in Patent Office: Days
• US Class Current: 606/108
• CPC Class Codes: A61B 17/12104 in an air passage
• CPC Class Codes: A61B 17/12136 Balloons
• CPC Class Codes: A61B 17/12186 liquid materials adapted to be injected
• CPC Class Codes: A61B 2017/12054 Details concerning the detachment of the occluding device from the introduction device
• CPC Class Codes: A61B 2017/12095 Threaded connection
• CPC Class Codes: A61B 2017/22067 Blocking; Occlusion A61B2017/22054 takes precedence
• CPC Class Codes: A61M 2025/1052 for temporarily occluding a vessel for isolating a sector
• CPC Class Codes: A61M 2025/1054 having detachable or disposable balloons
• CPC Class Codes: A61M 2210/1039 Lungs
• CPC Class Codes: A61M 25/0026 Multi-lumen catheters with stationary elements catheter assemblies comprising a catheter in combination with a guide tube, sheath or sleeve A61M2025/0681; catheters comprising telescoping coaxial elements A61M2025/0175
• CPC Class Codes: A61M 25/0069 Tip not integral with tube
• CPC Class Codes: A61M 25/007 Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
• CPC Class Codes: A61M 25/0075 Valve means
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00
• CPC Class Codes: A61M 25/1027 Making of balloon catheters

Abstract

This invention provides methods of treating a patient'"'"'s lung. One aspect of the invention provides a method of treating a lung including the following steps: inserting a collateral flow blocking agent delivery device into an air passageway of the lung; and delivering a collateral flow blocking agent to reduce airflow between a portion of the lung distal to the delivery device and the exterior of the patient. Another aspect of the invention provides a method of treating a lung including the step of delivering a collateral flow blocking agent to reduce airflow through openings in lung tissue caused by tissue degradation.

Claims

1. A method of treating a lung comprising:

inserting a collateral flow blocking agent delivery device into an air passageway of the lung; and

delivering a collateral flow blocking agent to reduce airflow between a portion of the lung distal to the delivery device and the exterior of the patient.

2. The method of claim 1 further comprising delivering a device into the lung to make circumferential contact with a wall of the air passageway.

3. The method of claim 2 further comprising expanding the device in the air passageway prior to delivering the collateral flow blocking agent.

4. The method of claim 3 further comprising removing the device after delivering the collateral flow agent.

5. The method of claim 1 further comprising removing the device after delivering the collateral flow agent.

6. The method of claim 1 wherein the collateral flow blocking agent comprises a plurality of microparticles.

7. The method of claim 6 wherein the microparticles comprise a polymeric binding material selected from a group consisting of poly(glycolic acid), poly-d, l-lactic acid, poly-l-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoester, poly(glycolic acid-caprolactone), polyanhydrides, polyphosphazines, albumin, casein, and waxes.

8. The method of claim 6 wherein the microparticles comprise protein microspheres formed from a material selected from a group consisting of albumin;

recombinant or naturally occurring human, animal, or vegetable proteins;

collagen;

gelatin;

casein;

soybean protein;

vegetable protein; and

keratin.

9. The method of claim 6 wherein the microparticles comprise a material selected from a group consisting of fatty acids;

lipids; and

derivatives thereof.

10. The method of claim 6 wherein the microparticles comprise synthetic polymeric particles formed from a material selected from a group consisting of HEMA (hydroxyethlymethcrylate);

AEMA (aminoethyl methacrylate);

DMEMA (N;

N dimethyl amino) and other acrylates;

acrylamides;

methacrylamides; and

styrene.

11. The method of claim 1 wherein the collateral flow blocking agent comprises a material selected from a group consisting of dextrans and other carbohydrate-based materials or derivatives thereof;

polyethylene glycol;

polyethylene oxide;

polyvinyl alchohol;

starch;

polyesters;

polyglycolic acid;

polylactic acid;

poly-1,4-dioxa-2-one, polyoxaltes;

polycarbonates;

copolymers of polyglycolic acid and polylactic acid;

polycaprolactone;

poly-b-hydroxybutyrate;

copolymers of epsilon-caprolactone and delta-valerolactone;

copolymers of epsilon-caprolactone and DL-dilactide;

polyester hydrogels;

polyvinylpyrrolidone;

polyamides;

gelatin;

albumin;

proteins;

collagen;

poly(orthoesters);

poly(anhydrides);

poly(alkyl-2-cyanoacrylates);

poly(dihydropyrans);

poly(acetals);

poly(phosphazenes);

poly(urethanes);

poly(dioxinones);

cellulose;

agarose;

agar;

block copolymers and derivatives of any of the aforementioned;

liposomes;

proliposomes.

12. The method of claim 1 wherein the collateral flow blocking agent comprises a viscous solution.

13. The method of claim 12 wherein the viscous solution comprises a material selected from a group consisting of hydrogels;

glycerol;

cellulose derivatives;

dextrans;

starch;

carbohydrate;

povidone;

polyethylene glycol;

polyethylene oxide;

polyvinyl alcohol;

diethyl aminoethyl (DEAE)—

sephadex;

collagen; and

albumin.

14. The method of claim 1 wherein the collateral flow blocking agent comprises a sealant.

15. The method of claim 14 wherein the collateral flow blocking agent comprises a two part sealant, the method further comprising delivering a first part of the sealant to a first lung lobe and a delivering a second part of the sealant to a second lung lobe.

16. A method of treating a lung comprising delivering a collateral flow blocking agent to reduce airflow through openings in lung tissue caused by tissue degradation.

17. The method of claim 16 further comprising:

delivering an expandable device to an air passageway within the lung; and

deploying the expandable device in the air passageway;

the step of delivering a collateral flow blocking agent comprising delivering a collateral flow blocking agent to reduce airflow through openings in lung tissue caused by tissue degradation distal to the expandable device.